Monday, 30 September 2002 00:00

ORANGEBURG, NY:  Radiancy, Inc., the global leader in light based skin therapies, has expanded the treatment applications for its LHET (Light Heat Energy) phototherapy systems by introducing a new light unit assembly (LUA), specially designed to clear mild to moderate psoriasis. The company has already introduced the new LHE application in Asia, Latin America, Europe and Canada, and expects to conduct additional clinical trials in the US at the beginning of 2004 in order to pursue marketing clearance by the US Food & Drug Administration (FDA).

Radiancy's new psoriasis LUA enables LHE phototherapy practitioners to perform a fourth treatment application in addition to vascular and pigmented lesions, acne phototherapy and photoepilation. Like the other LUAs, the modular psoriasis LUA attaches quickly to the Radiancy SkinStation?, SpaTouch? Pro, and Xtreme ClearT LHE phototherapy systems.

In clinical studies to date, LHE phototherapy combined with a salicylic acid regimen has been shown to be safe and effective for the treatment of mild to moderate plaque and guttate psoriasis. Clinical results show an average reduction of 65% in patients' Psoriasis Severity Index (PSI), a standard measure of the erythema, scaling and induration of a psoriasis plaque. Up to 75% clearance of psoriatic lesions has been reported.

According to Dr. Amos Leviav, Kaplan Hospital, Rehovot, Israel, a clinical investigator evaluating LHE in the treatment of psoriasis, " The Light and Heat Energy selective photothermolysis system delivers controlled heat simultaneously with the light pulse, has a large spot size and relieves itching after one week of treatment, making the system very efficient and sufficiently cost-effective to be considered for widespread use."

The LHE technology developed by Radiancy combines special wavelengths of pulsed light with direct heat to treat psoriasis from the inside out. The psoriasis LUA delivers green-yellow light that penetrates below the epidermis and through the plaque to the blood vessels that feed the plaque. There, by selective photothermolysis, the blood vessels are coagulated and destroyed, resulting in eventual destruction of the plaque and its replacement by healthy tissue. The LUA also delivers red light and direct heat into the lesion to reduce swelling and inflammation, and to relieve itching.
LHE powered systems employ a large spot size of 22 x 55 mm, allowing larger psoriatic areas to be treated for quicker patient relief using shorter treatment times. LHE is also cost-effective for the practitioner to operate because of its simplicity and capacity for multiple treatment applications using a single technology platform.

Radiancy also provides a variety of specially formulated cosmeceuticals based on mineral preparations from the Dead Sea that are used in conjunction with LHE phototherapy systems in the treatment of psoriasis, acne and other skin conditions.

Founded in 1998, Radiancy leads the world in developing unique medical products employing its proprietary LHE (Light Heat Energy) technology. The company's mission is to deliver light-based therapeutic systems that improve the lives of people while enhancing clinical practice. Radiancy serves a worldwide clinical community from its headquarters in Orangeburg, New York, and from offices in Europe, Asia and Latin America.